Printer Friendly

WYETH-AYERST'S LODINE(R) 400MG RECEIVES FDA MARKET CLEARANCE

 PHILADELPHIA, Aug. 9 /PRNewswire/ -- Wyeth-Ayerst Laboratories, division of American Home Products Corporation (NYSE: AHP) today announced FDA market clearance for Lodine(R) (etodolac) 400mg tablets.
 Indicated for the treatment of osteoarthritis and pain, this 400mg tablet adds a new higher strength of the already successful nonsteroidal anti-inflammatory drug Lodine.
 Lodine was the most successful prescription product launch in 1991 in the U.S. pharmaceutical industry and is today one of the most frequently prescribed nonsteroidals. Lodine 400mg will be available in early fall.
 Wyeth-Ayerst is a major research-oriented pharmaceutical company with leading products in the areas of women's healthcare, cardiovascular and metabolic disease therapies, central nervous system drugs, anti- inflammatory agents, vaccines and infant nutritionals. American Home Products Corporation is one of the world leaders in prescription drugs, packaged medicines, medical supplies, instrumentation and foods.
 /delval/
 -0- 8/9/93
 /CONTACT: Audrey Ashby of Wyeth-Ayerst Laboratories, 215-971-5823/
 (AHP)


CO: Wyeth-Ayerst Laboratories; American Home Products Corporation;
 U.S. Food and Drug Administration ST: Pennsylvania IN: MTC SU:


MP-LJ -- PH005 -- 0611 08/09/93 08:52 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 9, 1993
Words:175
Previous Article:ALLEGHENY GENERAL HOSPITAL STUDY: CRYOSURGERY MAY BE EFFECTIVE TREATMENT FOR PROSTATE CANCER
Next Article:NATIONAL LENTIL FESTIVAL TO BE HELD IN PULLMAN, WASH.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters